Display options
Cite
Niu H, Cui P, Shi W, et al. Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel). 2015;4(2):179-87doi: 10.3390/antibiotics4020179.
Niu, H., Cui, P., Shi, W., Zhang, S., Feng, J., Wang, Y., Sullivan, D., Zhang, W., Zhu, B., & Zhang, Y. (2015). Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel, Switzerland), 4(2), 179-87. https://doi.org/10.3390/antibiotics4020179
Niu, Hongxia, et al. "Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library." Antibiotics (Basel, Switzerland) vol. 4,2 (2015): 179-87. doi: https://doi.org/10.3390/antibiotics4020179
Niu H, Cui P, Shi W, Zhang S, Feng J, Wang Y, Sullivan D, Zhang W, Zhu B, Zhang Y. Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel). 2015 May 12;4(2):179-87. doi: 10.3390/antibiotics4020179. PMID: 27025620; PMCID: PMC4790332.
Copy Download .nbib Format: NLM
Share it on

Antibiotics (Basel). 2015 May 12;4(2):179-87. doi: 10.3390/antibiotics4020179.

Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library.

Antibiotics (Basel, Switzerland)

Hongxia Niu, Peng Cui, Wanliang Shi, Shuo Zhang, Jie Feng, Yong Wang, David Sullivan, Wenhong Zhang, Bingdong Zhu, Ying Zhang

Affiliations

  1. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. [email protected].
  2. Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China. [email protected].
  3. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. [email protected].
  4. Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China. [email protected].
  5. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. [email protected].
  6. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. [email protected].
  7. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. [email protected].
  8. Department of Clinical Microbiology Lab, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China. [email protected].
  9. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. [email protected].
  10. Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. [email protected].
  11. Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China. [email protected].

PMID: 27025620 PMCID: PMC4790332 DOI: 10.3390/antibiotics4020179

Abstract

Uropathogenic E. coli is a major cause of urinary tract infections (UTIs), but current antibiotics do not always effectively clear the persistent infection. To identify drugs that eliminate uropathogenic E. coli persisters, we screened a clinical drug library consisting of 1524 compounds using high throughput drug exposure assay in 96-well plates. Bacterial survival was assessed by growth on LB plates. We identified 14 drug candidates (tosufloxacin, colistin, sparfloxacin, moxifloxacin and gatifloxacin, enrofloxacin and sarafloxacin, octodrine, clofoctol, dibekacin, cephalosporin C, pazufloxacin, streptomycin and neomycin), which had high anti-persister activity. Among them, tosufloxacin and colistin had the highest anti-persister activity and could completely eradicate E. coli persisters in 3 days in vitro while the current UTI antibiotics failed to do so. Our findings may have implications for the development of a more effective treatment for UTIs.

Keywords: Escherichia coli; anti-persister activity; clinical drug library; persisters; urinary tract infection

References

  1. Am J Med. 2002 Jul 8;113 Suppl 1A:5S-13S - PubMed
  2. Emerg Microbes Infect. 2014 Jul;3(7):e49 - PubMed
  3. Clin Infect Dis. 2011 Mar 1;52(5):e103-20 - PubMed
  4. J Infect Dis. 1995 Dec;172(6):1536-41 - PubMed
  5. Infect Dis Clin North Am. 1997 Sep;11(3):551-81 - PubMed
  6. J Clin Microbiol. 2009 Jan;47(1):99-105 - PubMed
  7. Dan Med Bull. 2011 Apr;58(4):B4187 - PubMed
  8. Ann Pharmacother. 1999 Sep;33(9):960-7 - PubMed
  9. Antimicrob Agents Chemother. 2010 May;54(5):1855-63 - PubMed
  10. J Clin Microbiol. 2012 Dec;50(12):4002-7 - PubMed
  11. Clin Nephrol. 1992 Dec;38(6):318-23 - PubMed
  12. Antimicrob Agents Chemother. 1999 Jun;43(6):1317-23 - PubMed
  13. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5977-82 - PubMed
  14. J Med Microbiol. 2011 Apr;60(Pt 4):550-4 - PubMed
  15. Hinyokika Kiyo. 1994 Mar;40(3):279-84 - PubMed
  16. Nat Chem Biol. 2006 Aug;2(8):415-6 - PubMed
  17. Hinyokika Kiyo. 1992 Jan;38(1):129-34 - PubMed
  18. J Antimicrob Chemother. 1999 Aug;44(2):201-7 - PubMed
  19. Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8829-35 - PubMed
  20. J Infect Dis. 1995 Aug;172(2):440-5 - PubMed

Publication Types

Grant support